US FDA Examined 22 Cases Of Cancers In CAR-T Probe -Officials

NEW YORK: The U.S. Food and Drug Administration has been looking into 22 cases of T-cell cancers that occurred after treatment with CAR-T, two top FDA officials said on Wednesday, days after asking drugmakers to add a serious warning on the label of their cancer therapies that use the CAR-T technology.

In an article published in the New England Journal of Medicine, the officials – Dr. Peter Marks and Dr. Nicole Verdun – said that secondary malignancies have been reported in conjunction with five of the six available CAR-T products and that the cancers included T-cell lymphoma, T-cell large granular lymphocytosis, peripheral T-cell lymphoma, and cutaneous T-cell lymphoma.

CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body.

The products in question include Bristol Myers Squibb’s Breyanzi as well as Abecma, which BMS developed with 2seventy bio.

J&J unit Janssen and Legend Biotech’s Carvykti, Novartis AG’s Kymriah, and Gilead’s Tecartus and Yescarta are also a part of the investigation.

Marks and Verdun said the FDA has enough data about 14 of the cancer cases to determine that those cancers had manifested within two years of treatment.

They said that in three cases for which genetic sequencing had been done they had found evidence that the CAR-T product was most likely involved in development of the cancer.

Still, “with more than 27,000 doses of the six approved products having been administered in the United States, the overall rate of T-cell cancers among people receiving CAR-T therapies appears to be quite low, even if all reported cases are assumed to be related to treatment,” the FDA officials wrote.

Related Posts

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio, Inc. (Annovis), a phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced that…

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

The enforcement wing of Karnataka’s Food Safety and Drugs Control Department has seized medical devices and consumables worth ₹13.79 lakh from two establishments in Bengaluru’s Cottonpet area for alleged violations…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio receives US patent covering new crystalline form of buntanetap

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels